1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Quince Therapeutics, Inc.

Quince Therapeutics, Inc.

QNCX
Quince Therapeutics, Inc.US flagNASDAQ Global Select
31.32
USD
+0.77
- -
8.72MMarket Cap

Total Valuation

Quince Therapeutics, Inc. carries a market capitalization of 8.72M, placing it among publicly traded companies globally. Its enterprise value stands at -3.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.72M
Enterprise Value-3.83M

Share Statistics

Quince Therapeutics, Inc. currently has 689,539.00 shares outstanding.

Shares Outstanding689,539.00
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio0.89
P/TBV Ratio0.89
P/FCF Ratio-0.17
P/OCF Ratio-0.16

Financial Position

Quince Therapeutics, Inc. maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Current Ratio2.92
Quick Ratio2.82
Debt / Equity2.59
Debt / EBITDA-0.01
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-192.90
Return on Assets (ROA)-49.42
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-2.17M
Effective Tax RateN/A

Stock Price Statistics

Quince Therapeutics, Inc.'s stock has declined approximately -90.27329% over the past 52 weeks. The 50-day moving average sits at 24.91, while the 200-day moving average is 177.13.

Beta (5Y)N/A
52-Week Price Change-90.27329%
50-Day Moving Average24.91
200-Day Moving Average177.13
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -48.46M, while operating income came in at -48.61M.

RevenueN/A
Gross ProfitN/A
Operating Income-48.61M
Pretax Income-35.21M
Net Income-33.04M
EBITDA-48.46M
EBIT-48.61M
Earnings Per Share (EPS)-102.95

Balance Sheet

Quince Therapeutics, Inc. holds 18.16M in cash and equivalents against 406,000.00 in total debt, resulting in a net debt position of -18.16M. Total book value stands at 15.67M, with working capital of 16.81M providing operational flexibility.

Cash & Cash Equivalents18.16M
Total Debt406,000.00
Net Debt-18.16M
Equity (Book Value)15.67M
Book Value Per Share22.73
Working Capital16.81M

Cash Flow

Quince Therapeutics, Inc. produced -39.45M in operating cash flow over the past twelve months. After subtracting -204,000.00 in capital expenditures, free cash flow totaled -39.65M - equivalent to -123.57 per share.

Operating Cash Flow-39.45M
Capital Expenditures-204,000.00
Free Cash Flow-39.65M
FCF Per Share-123.57

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-195.75
FCF Yield-605.46

Stock Splits

Quince Therapeutics, Inc.'s most recent stock split took place on June 30, 2026 with a 20:1 split ratio.

Last Split Date6/30/2026
Split Ratio20:1

Scores

Quince Therapeutics, Inc. posts an Altman Z-Score of -26.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-26.83